Patent · US Active

Antibodies against epidermal growth factor receptor (EGFR) and uses thereof

US9226964B2 · kind B2 · utility

6Cited by

6References

37Claims

0Family size

Assignee

Merrimack Pharmaceuticals, Inc. · US

Inventors

Raghida BUKHALID · Melrose, US
Michael Feldhaus · Lebanon, US
Anne KING · Cambridge, US
Neeraj Kohli · Watertown, US
Eric Krauland · Lebanon, US
Jeffrey David KEARNS · Arlington, US
Alexey A. Lugovskoy · Woburn, US
Ulrik Nielsen · Quincy, US

Key dates

Filing date	Jan 3, 2014
Grant date	Jan 5, 2016
Priority date	—
Expiry date	Jan 3, 2034

Classification

Technology area (CPC G)Physics
CPC primaryG01N2800/52
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

Anti-EGFR antibodies, therapeutic compositions comprising combinations of anti-EGFR antibodies, as well as methods for using such antibodies and compositions to treat EGFR-related disorders (e.g., cancers), are disclosed.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.